Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | ACLY | P53396 | 1/20 | 0.30 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.30 |
| ▸ | TPMT | P51580 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5704414 | 0.86 | CA2 (0.39) | CA2CA4PTGS2HSD17B10TUBB1 | |
| SCHEMBL9804695 | 0.84 | CA2 (0.42) | CA2CA4PTGS2ALOX5APFEN1 | |
| SCHEMBL24536232 | 0.82 | POLB (0.39) | CA2CA4PTGS2TUBB1 | |
| SCHEMBL9377977 | 0.81 | CA2 (0.41) | CA2CA4PTGS2ALOX5APFEN1 | |
| SCHEMBL31015964 | 0.81 | CA2 (0.41) | CA2CA4PTGS2ALOX5APFEN1 | |
| SCHEMBL22341925 | 0.78 | CA2 (0.39) | CA2CA4ALOX5APFEN1HSD17B10 | |
| SCHEMBL6923912 | 0.78 | CA2 (0.43) | CA2CA4PTGS2HSD17B10ACLY | |
| SCHEMBL27628106 | 0.78 | CA2 (0.43) | CA2CA4ALOX5APFEN1HSD17B10 | |
| SCHEMBL4589673 | 0.77 | CA2 (0.46) | CA2CA4PTGS2ALOX5APFEN1 | |
| SCHEMBL22832058 | 0.76 | GAA (0.35) | PTGS2HSD17B10TUBB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-5194315-A | — | — | None | — | — | JP | disclosed |
| CN-114026073-B | Quinazolin-4-one derivatives for the treatment of BRAF related diseases and disorders | ARRAY生物制药公司 | 2024-08-23 | — | — | CN | disclosed |
| US-12037345-B2 | Heterobicyclic compounds for inhibiting the activity of SHP2 | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-16 | — | — | US | disclosed |
| US-11634409-B2 | Compounds for the treatment of BRAF-associated diseases and disorders | ARRAY BIOPHARMA INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-20220289721-A1 | COMPOUNDS FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | ARRAY BIOPHARMA INC. (US) | 2022-09-15 | — | — | US | disclosed |
| US-11414404-B2 | Compounds for the treatment of BRAF-associated diseases and disorders | ARRAY BIOPHARMA INC. (US) | 2022-08-16 | — | — | US | disclosed |
| EP-3990437-A1 | QUINAZOLIN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | Array Biopharma, Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| CN-114026073-A | Quinazolin-4-one derivatives for the treatment of BRAF related diseases and disorders | ARRAY生物制药公司 | 2022-02-08 | — | — | CN | disclosed |
| US-20200407344-A1 | COMPOUNDS FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | ARRAY BIOPHARMA INC. (US) | 2020-12-31 | — | — | US | disclosed |
| WO-2020261156-A1 | QUINAZOLIN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | ARRAY BIOPHARMA INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| JP-H05194315-A | PRODUCTION OF 2-CHLORO-4,5-DIFLUORO-3-METHOXYBENZOIC ACID | KYORIN PHARMACEUT CO LTD | 1993-08-03 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200407344-A1 | COMPOUNDS FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | BRAF, NRAS, RAF1 | CA2 3702/4885CA4 2672/4885PTGS2 4712/4885 |
| US-11634409-B2 | Compounds for the treatment of BRAF-associated diseases and disorders | BRAF, NRAS, RAF1 | CA2 3702/4885CA4 2672/4885PTGS2 4712/4885 |
| US-11414404-B2 | Compounds for the treatment of BRAF-associated diseases and disorders | BRAF, NRAS, RAF1 | CA2 3702/4885CA4 2672/4885PTGS2 4712/4885 |
| US-20220289721-A1 | COMPOUNDS FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | BRAF, NRAS, RAF1 | CA2 3702/4885CA4 2672/4885PTGS2 4712/4885 |
| US-12037345-B2 | Heterobicyclic compounds for inhibiting the activity of SHP2 | PTPN1, PTPN9, PTPN7 | CA2 1843/4885CA4 3053/4885PTGS2 4649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.